Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial

NARecruitingINTERVENTIONAL
Enrollment

441

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2036

Conditions
Rectal Cancer
Interventions
DIAGNOSTIC_TEST

High resolution MRI scan

MRI reporting of tumour but not mrTRG in the control arm = standard of care

DIAGNOSTIC_TEST

mrTRG assessment

Watch and wait offered for good responders Consider further treatment for poor responders

Trial Locations (10)

AB252ZN

RECRUITING

Aberdeen Royal Infirmary - NHS Grampion, Aberdeen

RG24 9NA

RECRUITING

Hampshire Hospitals NHS Foundation Trust, Basingstoke

ST4 6QS

RECRUITING

University Hospital of North Midlands NHS Trust - Royal Stoke, Stoke-on-Trent

SP2 8BJ

RECRUITING

Salisbury NHS Foundation Trust, Salisbury

BS2 8ED

RECRUITING

Bristol Royal Infirmary, Bristol

CO4 5JL

RECRUITING

Colchester General Hospital, Colchester

G75 8RG

RECRUITING

NHS Lanarkshire - Hairmyres Hospital, East Kilbride

DN33 2BA

RECRUITING

Diana Princess of Wales Hospital, Grimsby

TS19 8PE

RECRUITING

University Hospital of North Tees, Stockton-on-Tees

SM2 5PT

RECRUITING

Royal Marsden NHS Foundation Trust, Sutton

All Listed Sponsors
lead

Imperial College London

OTHER

NCT02704520 - Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial | Biotech Hunter | Biotech Hunter